Boston, MA – According to filings with the U.S. Securities and Exchange Commission, TearClear is raising $25,967,377.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Dempsey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TearClear

TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.

To learn more about TearClear, visit http://tearclear.com/

Contact:
Robert Dempsey, Chief Executive Officer
617-454-7251
https://www.linkedin.com/in/robert-j-dempsey/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved